Omeros | OMER - Sales Revenues


Omeros reported $0 in Sales Revenues for its fiscal quarter ending in March of 2022.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cytokinetics USD 19.35M 1.59M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Rockwell Medical USD 25.83M 3.15M Jun/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xoma USD 25K 5M Sep/2024